The WHO’s revised classification system for CNS tumours now incorporates genetic features, including the mutation status of isocitrate dehydrogenase (IDH) genes. A new article proposes that mutational status of CDKN2A and CDKN2B should also be included to facilitate grading of IDH-mutated gliomas with both prognostic and clinical relevance.
- Christopher J. Pirozzi
- Hai Yan